Studies demonstrate that YY1 functions as a transcriptional repressor of FEN1, and YY1 dissociates from the FEN1 promoter to increase its expression under DNA-damaging agent (mitomycin and taxol) treatment, consequently promoting resistance to drugs in breast cancer cells [93,94,95]. Here, FEN1 is linked to breast cancer.